Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1.

Barker DF, Husain A, Neale JR, Martini BD, Zhang X, Doll MA, States JC, Hein DW.

Pharmacogenet Genomics. 2006 Jul;16(7):515-25.

2.

Identification of the major promoter and non-coding exons of the human arylamine N-acetyltransferase 1 gene (NAT1).

Husain A, Barker DF, States JC, Doll MA, Hein DW.

Pharmacogenetics. 2004 Jul;14(7):397-406.

PMID:
15226672
4.
5.

NATb/NAT1*4 promotes greater arylamine N-acetyltransferase 1 mediated DNA adducts and mutations than NATa/NAT1*4 following exposure to 4-aminobiphenyl.

Millner LM, Doll MA, Cai J, States JC, Hein DW.

Mol Carcinog. 2012 Aug;51(8):636-46. doi: 10.1002/mc.20836. Epub 2011 Aug 11.

6.

Functional analysis of arylamine N-acetyltransferase 1 (NAT1) NAT1*10 haplotypes in a complete NATb mRNA construct.

Millner LM, Doll MA, Stepp MW, States JC, Hein DW.

Carcinogenesis. 2012 Feb;33(2):348-55. doi: 10.1093/carcin/bgr273. Epub 2011 Nov 22. Erratum in: Carcinogenesis. 2012 Jul;33(7):1431.

7.

Functional analysis of the human N-acetyltransferase 1 major promoter: quantitation of tissue expression and identification of critical sequence elements.

Husain A, Zhang X, Doll MA, States JC, Barker DF, Hein DW.

Drug Metab Dispos. 2007 Sep;35(9):1649-56. Epub 2007 Jun 25.

8.

Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues.

Husain A, Zhang X, Doll MA, States JC, Barker DF, Hein DW.

Drug Metab Dispos. 2007 May;35(5):721-7. Epub 2007 Feb 7.

10.

Glucocorticoid receptor-mediated transcriptional regulation of N-acetyltransferase 1 gene through distal promoter.

Bonamassa B, Ma Y, Liu D.

AAPS J. 2012 Sep;14(3):581-90. doi: 10.1208/s12248-012-9370-5. Epub 2012 May 30.

11.

Functional effects of genetic polymorphisms in the N-acetyltransferase 1 coding and 3' untranslated regions.

Zhu Y, States JC, Wang Y, Hein DW.

Birth Defects Res A Clin Mol Teratol. 2011 Feb;91(2):77-84. doi: 10.1002/bdra.20763. Epub 2011 Feb 2.

12.
13.

Induction of human arylamine N-acetyltransferase type I by androgens in human prostate cancer cells.

Butcher NJ, Tetlow NL, Cheung C, Broadhurst GM, Minchin RF.

Cancer Res. 2007 Jan 1;67(1):85-92.

14.

Arylamine N-acetyltransferase 1 gene regulation by androgens requires a conserved heat shock element for heat shock factor-1.

Butcher NJ, Minchin RF.

Carcinogenesis. 2010 May;31(5):820-6. doi: 10.1093/carcin/bgq042. Epub 2010 Feb 22.

PMID:
20176657
15.

Promoter hypomethylation of the N-acetyltransferase 1 gene in breast cancer.

Kim SJ, Kang HS, Chang HL, Jung YC, Sim HB, Lee KS, Ro J, Lee ES.

Oncol Rep. 2008 Mar;19(3):663-8.

PMID:
18288399
16.

Syrian hamster monomorphic N-acetyltransferase (NAT1) alleles: amplification, cloning, sequencing, and expression in E. coli.

Ferguson RJ, Doll MA, Rustan TD, Baumstark BR, Hein DW.

Pharmacogenetics. 1994 Apr;4(2):82-90.

PMID:
8081415
17.

Primary acute lymphoblastic leukemia cells use a novel promoter and 5'noncoding exon for the human reduced folate carrier that encodes a modified carrier translated from an upstream translational start.

Flatley RM, Payton SG, Taub JW, Matherly LH.

Clin Cancer Res. 2004 Aug 1;10(15):5111-22. Erratum in: Clin Cancer Res. 2005 Oct 15;11(20):7586.

18.

Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity.

Wang D, Para MF, Koletar SL, Sadee W.

Pharmacogenet Genomics. 2011 Oct;21(10):652-64. doi: 10.1097/FPC.0b013e3283498ee9.

19.

Phenotype of the most common "slow acetylator" arylamine N-acetyltransferase 1 genetic variant (NAT1*14B) is substrate-dependent.

Millner LM, Doll MA, Cai J, States JC, Hein DW.

Drug Metab Dispos. 2012 Jan;40(1):198-204. doi: 10.1124/dmd.111.041855. Epub 2011 Oct 18.

20.

Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: a potential marker in estrogen receptor-positive tumors.

Wakefield L, Robinson J, Long H, Ibbitt JC, Cooke S, Hurst HC, Sim E.

Genes Chromosomes Cancer. 2008 Feb;47(2):118-26.

PMID:
17973251

Supplemental Content

Support Center